Cargando…
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026948/ https://www.ncbi.nlm.nih.gov/pubmed/36626630 http://dx.doi.org/10.1097/HEP.0000000000000004 |
_version_ | 1784909622476275712 |
---|---|
author | Younossi, Zobair M. Golabi, Pegah Paik, James M. Henry, Austin Van Dongen, Catherine Henry, Linda |
author_facet | Younossi, Zobair M. Golabi, Pegah Paik, James M. Henry, Austin Van Dongen, Catherine Henry, Linda |
author_sort | Younossi, Zobair M. |
collection | PubMed |
description | NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using random-effects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N=9,361,716) met eligibility criteria. Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46–31.87) in 1990–2006 to 34.59% (29.05–40.57) (p=0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%–59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East Asia (33.07%, 18.99%–51.03%), North America (31.20%, 25.86%–37.08%), East Asia (29.71%, 25.96%–33.76%), Asia Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68–23.67) for all-cause mortality; 4.20 (1.34–7.05) for cardiac-specific mortality; 2.83 (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00–2.21) for liver-specific mortality. CONCLUSIONS: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels. |
format | Online Article Text |
id | pubmed-10026948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-100269482023-03-21 The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review Younossi, Zobair M. Golabi, Pegah Paik, James M. Henry, Austin Van Dongen, Catherine Henry, Linda Hepatology Original Articles: Steatohepatitis NAFLD is a leading cause of liver-related morbidity and mortality. We assessed the global and regional prevalence, incidence, and mortality of NAFLD using an in-depth meta-analytic approach. APPROACH AND RESULTS: PubMed and Ovid MEDLINE were searched for NAFLD population-based studies from 1990 to 2019 survey year (last published 2022) per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Meta-analysis was conducted using random-effects models. Bias risk assessment was per Joanna Briggs Institute. Of 2585 studies reviewed, 92 studies (N=9,361,716) met eligibility criteria. Across the study period (1990–2019), meta-analytic pooling of NAFLD prevalence estimates and ultrasound-defined NAFLD yielded an overall global prevalence of 30.05% (95% CI: 27.88%–32.32%) and 30.69% (28.4–33.09), respectively. Global NAFLD prevalence increased by +50.4% from 25.26% (21.59–29.33) in 1990–2006 to 38.00% (33.71–42.49) in 2016–2019 (p<0.001); ultrasound-defined NAFLD prevalence increased by +38.7% from 25.16% (19.46–31.87) in 1990–2006 to 34.59% (29.05–40.57) (p=0.029). The highest NAFLD prevalence was in Latin America 44.37% (30.66%–59.00%), then Middle East and North Africa (MENA) (36.53%, 28.63%–45.22%), South Asia (33.83%, 22.91%–46.79%), South-East Asia (33.07%, 18.99%–51.03%), North America (31.20%, 25.86%–37.08%), East Asia (29.71%, 25.96%–33.76%), Asia Pacific 28.02% (24.69%–31.60%), Western Europe 25.10% (20.55%–30.28%). Among the NAFLD cohort diagnosed without a liver biopsy, pooled mortality rate per 1000 PY was 12.60 (6.68–23.67) for all-cause mortality; 4.20 (1.34–7.05) for cardiac-specific mortality; 2.83 (0.78–4.88) for extrahepatic cancer-specific mortality; and 0.92 (0.00–2.21) for liver-specific mortality. CONCLUSIONS: NAFLD global prevalence is 30% and increasing which requires urgent and comprehensive strategies to raise awareness and address all aspects of NAFLD on local, regional, and global levels. Lippincott Williams & Wilkins 2023-04 2023-01-03 /pmc/articles/PMC10026948/ /pubmed/36626630 http://dx.doi.org/10.1097/HEP.0000000000000004 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Original Articles: Steatohepatitis Younossi, Zobair M. Golabi, Pegah Paik, James M. Henry, Austin Van Dongen, Catherine Henry, Linda The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review |
title | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review |
title_full | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review |
title_fullStr | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review |
title_full_unstemmed | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review |
title_short | The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review |
title_sort | global epidemiology of nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash): a systematic review |
topic | Original Articles: Steatohepatitis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026948/ https://www.ncbi.nlm.nih.gov/pubmed/36626630 http://dx.doi.org/10.1097/HEP.0000000000000004 |
work_keys_str_mv | AT younossizobairm theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT golabipegah theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT paikjamesm theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT henryaustin theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT vandongencatherine theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT henrylinda theglobalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT younossizobairm globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT golabipegah globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT paikjamesm globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT henryaustin globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT vandongencatherine globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview AT henrylinda globalepidemiologyofnonalcoholicfattyliverdiseasenafldandnonalcoholicsteatohepatitisnashasystematicreview |